NO20090457L - Oksazolidon derivativer som PR modulatorer - Google Patents

Oksazolidon derivativer som PR modulatorer

Info

Publication number
NO20090457L
NO20090457L NO20090457A NO20090457A NO20090457L NO 20090457 L NO20090457 L NO 20090457L NO 20090457 A NO20090457 A NO 20090457A NO 20090457 A NO20090457 A NO 20090457A NO 20090457 L NO20090457 L NO 20090457L
Authority
NO
Norway
Prior art keywords
hormone
compounds
treatment
modulators
intake
Prior art date
Application number
NO20090457A
Other languages
English (en)
Inventor
Andrew Fensome
Ronald Charles Bernotas
Casey Cameron Mccomas
Michael Anthony Marella
Gavin David Heffernan
Edward George Melenski
Thomas Joseph Commons
Jr Richard Page Woodworth
Michael Byron Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20090457L publication Critical patent/NO20090457L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser med følgende struktur er beskrevet: hvor R1, R2, R5, R6, V, X, Y, Z og Q er beskrevet her eller et farmasøytisk akseptabelt salt, tautomer, metabolitt eller prodrug derav. Disse forbindelser er anvendelige for behandling av en rekke hormonrelaterte lidelser omfattende prevensjon, behandling av eller forhindring fibroider, endometriose, dysfunksjonell blødning, uterin leiomyomata, polycystisk eggstokk-syndrom eller hormon-avhengig karsinomer, tilveiebringer hormonerstatningsterapi, stimulerende matinntak eller synkroniserende brunst.
NO20090457A 2006-08-15 2009-01-29 Oksazolidon derivativer som PR modulatorer NO20090457L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83789806P 2006-08-15 2006-08-15
PCT/US2007/017931 WO2008021331A2 (en) 2006-08-15 2007-08-13 Oxazolidone derivatives as pr modulators

Publications (1)

Publication Number Publication Date
NO20090457L true NO20090457L (no) 2009-04-27

Family

ID=39082681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090457A NO20090457L (no) 2006-08-15 2009-01-29 Oksazolidon derivativer som PR modulatorer

Country Status (22)

Country Link
US (1) US7618990B2 (no)
EP (1) EP2054410A2 (no)
JP (1) JP2010500409A (no)
KR (1) KR20090039774A (no)
CN (1) CN101501031B (no)
AR (1) AR062327A1 (no)
AU (1) AU2007284599B2 (no)
BR (1) BRPI0716622A2 (no)
CA (1) CA2659208A1 (no)
CR (1) CR10617A (no)
GT (1) GT200900032A (no)
IL (1) IL196886A0 (no)
MX (1) MX2009001698A (no)
NO (1) NO20090457L (no)
NZ (1) NZ574753A (no)
PE (1) PE20070753A1 (no)
RU (1) RU2009105113A (no)
SA (1) SA07280440B1 (no)
SV (1) SV2009003168A (no)
TW (1) TW200815428A (no)
WO (1) WO2008021331A2 (no)
ZA (1) ZA200901055B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
PE20081803A1 (es) * 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CN101525310B (zh) * 2009-04-21 2019-04-16 大连九信精细化工有限公司 1-苯甲酰基-3-(2-羟基-1，1-二甲基乙基)硫脲的合成方法
ES2550319T3 (es) * 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9120818B2 (en) * 2010-12-14 2015-09-01 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
US9902719B2 (en) 2014-07-03 2018-02-27 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493565A (en) 1966-03-14 1970-02-03 Squibb & Sons Inc 3-amino-5-(nitrofuryl)-1,2,4-oxadiazole derivatives
DE1670338A1 (de) 1966-03-14 1972-08-10 Heyden Chem Fab Verfahren zur Herstellung von antimikrobiell wirksamen Nitrofuranderivaten
NL6809997A (no) * 1967-08-04 1969-02-06
GB1224995A (en) 1968-09-20 1971-03-10 Delalande Sa New 5-propargyloxymethyl-2-substituted oxazolidinones and their process of preparation
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4293558A (en) * 1975-10-28 1981-10-06 Eli Lilly And Company Antiviral thiazolinyl benzimidazoles and derivatives
US4008243A (en) * 1975-11-19 1977-02-15 Eli Lilly And Company Antiviral thiazolinyl or thiazinyl benzimidazole esters
US4268679A (en) * 1980-02-19 1981-05-19 Ppg Industries, Inc. 3-[5- or 3-Substituted-5- or 3-isoxazolyl]-1-allyl or alkyl-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
US4426527A (en) * 1982-02-12 1984-01-17 Ppg Industries, Inc. 3-[5- Or 3-substituted-1,2,4-oxadiazol-3- or -5-yl]-1-substituted-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
DE3227329A1 (de) 1982-07-22 1984-01-26 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 2-n,n-disubstituierten aminothiazolen
US4756744A (en) * 1985-06-24 1988-07-12 Ppg Industries, Inc. Herbicidally active 4-aminoalkylamino-3-isoxazolyl-2-imidazolidinone derivatives
DE3723797A1 (de) 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
CA2095429A1 (en) 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
ES2245660T3 (es) 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
WO1995015955A1 (de) 1993-12-06 1995-06-15 Basf Aktiengesellschaft 2,4-diaminothiazole und ihre herstellung
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19649095A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue Heteroaryl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
JP3192662B2 (ja) 1996-07-31 2001-07-30 日研化学株式会社 ６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
US5819742A (en) * 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
CA2302417A1 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
EP1049682A1 (en) * 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6562844B2 (en) * 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
DE10034622A1 (de) 2000-07-17 2002-01-31 Bayer Ag Substituierte Imidazol-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
DE10034628A1 (de) 2000-07-17 2002-01-31 Bayer Ag Pyridinhaltige Oxazolidinone als Cytokin-Inhibitoren
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
GB0118407D0 (en) 2001-07-27 2001-09-19 Cipla Ltd Oxazolidinone derivatives as antibacterial agents
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
PL375532A1 (en) 2002-08-08 2005-11-28 Smithkline Beecham Corporation Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
TWI324596B (en) * 2002-08-26 2010-05-11 Nat Health Research Institutes Imidazolamino compounds
AU2003258433A1 (en) 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
US7514567B2 (en) 2003-07-08 2009-04-07 Astrazeneca Ab Oxazolidinone nicotinic acetylcholine receptor agonists

Also Published As

Publication number Publication date
GT200900032A (es) 2011-03-29
BRPI0716622A2 (pt) 2013-10-08
NZ574753A (en) 2011-04-29
US20080045556A1 (en) 2008-02-21
SV2009003168A (es) 2010-01-14
CA2659208A1 (en) 2008-02-21
KR20090039774A (ko) 2009-04-22
SA07280440B1 (ar) 2010-10-20
TW200815428A (en) 2008-04-01
JP2010500409A (ja) 2010-01-07
MX2009001698A (es) 2009-02-25
AU2007284599B2 (en) 2011-07-21
CR10617A (es) 2009-03-12
PE20070753A1 (es) 2008-08-14
ZA200901055B (en) 2009-12-30
CN101501031A (zh) 2009-08-05
RU2009105113A (ru) 2010-09-27
CN101501031B (zh) 2012-02-01
IL196886A0 (en) 2009-11-18
US7618990B2 (en) 2009-11-17
WO2008021331A3 (en) 2008-05-22
EP2054410A2 (en) 2009-05-06
AU2007284599A1 (en) 2008-02-21
AR062327A1 (es) 2008-10-29
WO2008021331A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
NO20090457L (no) Oksazolidon derivativer som PR modulatorer
WO2008021338A3 (en) Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021339A3 (en) Pyrrolidine and related derivatives useful as pr modulators
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20084364L (no) Azetidin derivater som G-protein koblet reseptor (GPR119) agonister
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20084307L (no) Heterocykliske GPCR agonister
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
TW200806311A (en) Neuropeptide-2 receptor-agonists
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20076134L (no) Benzamidderivater og anvendelser derav
DK1807434T3 (da) Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20071138L (no) Piperazinderivater som er nyttige for behandling av gastrointestinallidelser
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
GT200600337A (es) Uso de moduladores del receptor de progesterona
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application